Navigation Links
PAREXEL Enhances Early Phase Clinical Development Offering for Central Nervous System Studies
Date:6/17/2008

contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2008 a
'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting
2. PAREXEL Reaches Agreement To Acquire ClinPhone
3. PAREXEL International to Present at Goldman Sachs 29th Annual Global Healthcare Conference
4. PAREXEL Product Development and Regulatory Experts to Attend the 2008 BIO International Convention
5. PAREXEL Appoints Leading Biostatistician Dr. Imogene Grimes to Vice President of Data Sciences Strategic Services
6. PAREXEL Reports Third Quarter Fiscal Year 2008 Financial Results
7. PAREXEL Experts to Offer Insights Into Outsourcing Best Practices at 17th Annual Partnerships with CROs Conference
8. PAREXEL Appoints Leading Central Nervous System Experts to Its Global Clinical Pharmacology Business
9. PAREXEL International Expands Relationship with Synchron Research in India and Divests Bioanalytical Laboratory in France
10. PAREXEL Announces Date of Third Quarter Fiscal Year 2008 Earnings Release and Conference Call
11. PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... cell phones to cars and flashlights, batteries play ... technology companies constantly are seeking ways to improve ... time using a water-based solution, researchers at the ... more efficient nuclear battery that could be used ... source in automobiles and also in complicated applications ...
(Date:9/16/2014)... 16, 2014 BlueInGreen® , ... efficient method for delivering dissolved gases into liquids, ... as a manufacturer’s representative firm to its ... products for municipal water and wastewater applications in ... H2Flow was founded in 1992 and serves Quebec ...
(Date:9/16/2014)... Sept. 16, 2014  Donald Fresne, President and CEO of ... Stephan Vagner , PhD to its Scientific Advisory Committee. ... Toulouse, France , performed research at Embl (European ... at Inserm, the French institute of health and medical research. ... at the Curie Institute, Orsay, France , ...
(Date:9/16/2014)... 16, 2014  The Council for Entrepreneurial Development ... in the country, today released a mid-year update ... It showed that in the first ... startups in the technology, life science, advanced ... from a variety of sources. Significant investment in technology ...
Breaking Biology Technology:BlueInGreen® Expands into Canada – Signs Representative Agreement with H2Flow Equipment Inc. 2New Appointment to the Scientific Advisory Committee at Egenix, Inc. 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 3CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 4
... Annual Revenues Up, Net Loss Down, Cash Position Strong, as Pipeline ... ... (Nasdaq: EXEL ) today reported financial results for the full,year and ... $113.5 million, compared to $98.7 million in,2006. The increase in revenues for ...
... PALO ALTO, Calif., Feb. 14 Telik, Inc.,(Nasdaq: ... webcast will,be held on Thursday, February 21, 2008 at ... release earlier that day of the company,s,financial results for ... The conference call will be accessible via Telik,s ...
... Executives from Senexis,and O2H, both located in Cambridge, ... synthetic and computational chemistry services to the drug,discovery ... "We believe our collaboration with O2H leverages the ... search for new,therapeutics to treat ageing-related diseases by ...
Cached Biology Technology:Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 2Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 3Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 4Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 5Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 6Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 7Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 8Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 9Senexis and O2H (Oxygen Healthcare) Announce Medicinal Chemistry Collaboration 2
(Date:9/16/2014)... Sept. 16, 2014  Valencell, Inc., a leader in ... one of 18 "Showcase Companies" representing North ... annual CED Tech Venture Conference on September 16-17 th ... Center in Raleigh, North Carolina . ... a discussion during the "Digital Health Spotlight Sector" on ...
(Date:9/15/2014)... digestion to disease resistance. Despite the fact that tropical ... planet, more is known about belly-button bacteria than bacteria ... working on Panama,s Barro Colorado Island discovered that small ... more than 400 different kinds of bacteria. The combined ... different kinds. , Bacteria in tropical forests may also ...
(Date:9/15/2014)... a common epilepsy drug to a morphine regimen can ... Moreover, the combination can reduce the dosage of the ... of pain researchers at Indiana University. , The result ... pain, a difficult-to-treat condition often felt in the arms ... "There is a huge unmet need for better treatments ...
Breaking Biology News(10 mins):Valencell, Inc. Selected as 'Showcase Company' at CED Tech Venture Conference 2014 2Smithsonian scientists discover tropical tree microbiome in Panama 2IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2
... ago, the German Physical Society (DPG) has introduced the ... interdisciplinary applications of physics. The Prize, endowed with 5000 ... instrument to encourage research in this direction. This ... Max Planck Institute for Evolutionary Biology in Pln. He ...
... , New Rochelle, NY -- A novel method for ... help advance research on tissue engineering and regeneration, as ... Part C, Methods, a peer-reviewed journal from Mary Ann ... free online at the Tissue Engineering website ...
... proteins that actively pump a wealth of molecules across ... functions in humans. Genetic defects in ABC transporters can ... cystic fibrosis, and certain ABC transporters also cause resistance ... increased amounts of ABC transporters that pump chemotherapeutic substances ...
Cached Biology News:'Young Scientist Award for Socio- and Econophysics 2012' for Arne Traulsen 2
These disposable button tethers are designed for rat infusion studies lasting more than 2 weeks. After one to two weeks the subcutaneous tissue will grow into the Dacron mesh, making the sutures irre...
Bethyl Laboratories Epitope Retrieval Buffer-Reduced pH will unmask antigenic sites from formaldehyde fixation and allow for subsequent immunostaining. Shelf-Life: 1 year from date of receipt...
Mycoplasma and virus tested...
Mycoplasma and virus tested...
Biology Products: